SensoDetect Advances Strategic Collaboration with Saudi Health Leadership to Integrate Objective Neurodevelopmental Screening Tools

SensoDetect AB today announced a high-level strategic meeting with a delegation from the Kingdom of Saudi Arabia, including the Saudi Arabia Health Holding Institution, the National Unified Procurement Company (NUPCO), and the Saudi Public Health Authority. The meeting, part of the delegation's visit to the Karolinska Institute in Stockholm, focused on integrating SensoDetect's evidence-based, objective neurodevelopmental screening technologies into the Kingdom's public health infrastructure. These institutions collectively play central roles in healthcare transformation, public health strategy, and national procurement within the Kingdom under Saudi Vision 2030.

The Health Holding Institution was led by its Chairman of the Board, His Excellency Fahd bin Abdulrahman Al-Jalajel, who also serves as the Minister of Health of the Kingdom of Saudi Arabia. Under his leadership, the institution drives major improvements in healthcare quality, efficiency, preventive services, and digital transformation.

Technology and Clinical Validation Presented
SensoDetect presented data on its flagship product, the SensoDetect ADHD screening tool, which is commercially available and clinically validated for use in primary care settings for children aged six and above. The technology utilizes Auditory Brainstem Response (ABR) to provide an objective, data-driven assessment, reducing subjectivity in traditional diagnostic methods.

Furthermore, SensoDetect introduced its research and development pipeline, specifically a pre-clinical initiative for the early detection of Autism Spectrum Disorder (ASD). This initiative aims to identify biomarkers for ASD in infancy, a critical period for early intervention, which can significantly improve long-term developmental outcomes.

Established In-Kingdom Footprint and Strategic Alignment
SensoDetect highlighted its established operational and clinical foundation within Saudi Arabia, a key de-risking factor for investors. This includes:

The Saudi leadership identified a strong alignment between SensoDetect’s technology and national public health objectives, including:

Forward-Looking Strategic Initiatives
The parties mutually agreed to advance discussions focusing on:

"This engagement represents a significant opportunity to address a substantial public health need with our objective screening technology," said Dr. Mohamed Atwa, Head of Clinical Research at SensoDetect. "Our solutions are designed for scalability and integration, directly supporting the efficiency and digital health goals of our potential partners."

A representative from SensoDetect's leadership team added, "The systematic and integrated approach of the Saudi healthcare leadership is impressive. This dialogue is a pivotal step toward a partnership that could meaningfully expand our addressable market and impact the lives of millions of children."